Allurion Technologies Appeals NYSE Delisting Decision Following FDA Approval of Smart Capsule

Key Points from the Report

• Allurion Technologies, Inc. (OTCID: ALUR) has formally appealed the New York Stock Exchange (NYSE) decision to initiate delisting proceedings against its securities.
• The NYSE move is based on Section 802.01B of the Listed Company Manual, which requires companies to maintain an average global market capitalization of at least \$15 million over a consecutive 30 trading day period.
• Allurion’s recent FDA approval for its flagship product, the Allurion Gastric Balloon System featuring the Allurion Smart Capsule, is a catalyst for the company’s plan to regain compliance or seek listing on NYSE American.
• The company is currently executing a detailed plan shared with NYSE management to strengthen its balance sheet and fund commercialization of the Smart Capsule in the U.S.
• While appealing the NYSE decision, Allurion’s securities are trading on the OTCID exchange until it regains compliance or secures a new listing.
• CEO Dr. Shantanu Gaur emphasized the company’s confidence in executing the plan and highlighted the market opportunity: over 100 million Americans suffer from obesity, with 20 million having tried and discontinued GLP-1 therapies.
• The company’s plan centers on leveraging FDA approval to accelerate commercialization, balance sheet strengthening, and listing compliance.

Important Shareholder Considerations and Potential Price Sensitivity

• Delisting proceedings are a major risk. Continued listing on a major exchange like NYSE/American is crucial for liquidity, investor confidence, and access to capital. Failure to regain compliance could materially impact share value.
• FDA approval of the Allurion Gastric Balloon System is a significant milestone and could positively affect share price if commercialization succeeds and listing is restored.
• The company has no assurance that efforts to regain compliance will succeed. Investors should be aware that the appeal and execution of the plan might not guarantee resumption of NYSE trading.
• Risk factors: The company’s forward-looking statements are subject to risks including regulatory hurdles, commercialization challenges, competition (especially from GLP-1 drugs), economic conditions, and changing industry regulations.
• Allurion is targeting a large market and claims to be pioneering metabolically healthy weight loss, but execution risks remain.
• The company is currently trading on the OTCID exchange, which may affect liquidity and valuation until listing on NYSE/NYSE American is restored.

Detailed Narrative for Investors

Allurion Technologies, Inc., a leader in the field of metabolically healthy weight loss, has announced an appeal against the NYSE’s decision to begin delisting proceedings for its securities. The NYSE’s move is based on the company’s failure to maintain a minimum global market capitalization of \$15 million over the last 30 trading days, as stipulated by Section 802.01B of its Listed Company Manual.

The company recently received FDA approval for its innovative Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. This regulatory milestone has become the cornerstone of Allurion’s plan to regain compliance with NYSE listing standards or secure an initial listing on NYSE American. The plan includes strengthening the company’s balance sheet and funding the commercialization of the Smart Capsule in the U.S.

CEO Dr. Shantanu Gaur expressed optimism about the company’s prospects, stating that the FDA approval is the first step in a larger strategy. The company is targeting a substantial market: more than 100 million Americans are affected by obesity, including 20 million who have tried and discontinued GLP-1 therapies. Allurion aims to provide a new standard for weight loss and capitalize on its unique positioning.

The company’s management has been in regular contact with NYSE regarding its step-by-step plan, which is currently being executed. However, Allurion cautions investors that there is no guarantee these efforts will result in successful re-listing or compliance restoration. During this interim period, Allurion’s securities are trading on the OTCID exchange, which may impact liquidity and valuation.

Forward-looking statements in the company’s release underscore risks and uncertainties, including regulatory and commercialization challenges, competitive pressures (notably from GLP-1 drugs), economic and political factors, and industry changes. These risks are detailed in the company’s SEC filings, and investors are warned against placing undue reliance on such statements.

Investor Contact

Email: [email protected]

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The information is based on publicly available reports and statements from Allurion Technologies, Inc. Investors should conduct their own due diligence and consult their financial advisors before making any investment decisions. Allurion’s forward-looking statements are subject to risks and uncertainties that may affect actual results. The company undertakes no obligation to update any forward-looking statements except as required by law.

View ALLURION TECHNOLOGIES, INC. Historical chart here